NeuroDerm receives funding for phase 2 clinical trial of Parkinson’s disease drug
Part of the Foundation’s 2013 Therapeutic Pipeline program, the grant will support an upcoming phase 2 clinical trial with the subcutaneously delivered drug that is currently under development.